Your AI-Trained Oncology Knowledge Connection!
Stimuli for biologic aging include ionizing radiation, ultraviolet light, diet, exercise, oxidative stresses, and perhaps, worst of all, smoking. All of these can trigger intracellular processes, including DNA methylation, or epigenetic change, telomere shortening and damage, DNA damage, and mitochondrial dysfunction.
A wave of approvals and a rapidly evolving treatment landscape could make the next decade a watershed period in breast cancer care.
Even in 2021, disparities in outcomes of younger women with breast cancer vs their older counterparts remain; addressing behavioral issues and psychological concerns in this population could vastly improve their quality of life, treatment adherence, and ultimately, survival.
Off Our Chests: A Candid Tour Through the World of Cancer is a memoir that dives into Liza Marshall’s breast cancer journey.
Although phase 3 data suggest that the addition of checkpoint inhibitors to neoadjuvant chemotherapy could improve pathologic complete response rates for patients with early-stage triple-negative breast cancer, immature data and the risk of long-term toxicity indicate that the therapy is not ready for primetime
Kevin Kalinsky, MD, MS, discusses the potential of antibody-drug conjugates across breast cancer subtypes.
Hope S. Rugo, MD, discusses the benefit of margetuximab-cmkb in patients with HER2-positive breast cancer who have received prior HER2-targeted therapies.
The introduction of new therapies for patients with recurrent HER2-positive metastatic breast cancer has resulted in a crowded landscape for third-line treatments and beyond, raising questions about how best to sequence a wealth of options.
Targeted agents and chemotherapy regimens are at the crux of systemic research efforts focused on improving outcomes for patients with breast cancer who have brain metastases and/or leptomeningeal disease.
Debu Tripathy, MD, discusses some of the unanswered clinical questions that remain for patients with HER2-positive disease and some strategies for personalizing treatment in the neoadjuvant and adjuvant settings.
Debu Tripathy, MD, discusses efforts being made to minimize the risk of disease recurrence in patients with early-stage HER2-positive breast cancer.
Olufunmilayo Falusi Olopade, MD, FACP, discusses racial disparities in breast cancer outcomes.
With the identification of numerous molecular abnormalities that can affect treatment and the course of disease in patients with breast cancer, it’s become understood that genetic profiling can define clinical trial eligibility, the presence or absence of aberrations help to drive treatment decisions, and variants can be predictive for response or resistance.
Although there is evidence to suggest that surgery with or without radiation therapy can be utilized in some patients with stage IV breast cancer who have experienced locoregional progression or symptoms to some success with regard to locoregional disease control, most patients will not achieve a survival benefit.
CDK4/6 inhibitors plus aromatase inhibitors have shown benefit as frontline treatment for patients with hormone receptor–positive, HER2-negative advanced breast cancer, but more data are needed to determine their role as adjuvant therapy before they are adopted into standard practice for patients with early-stage disease.
Adam M. Brufsky, MD, PhD, discusses the role of neoadjuvant chemotherapy in triple-negative breast cancer.
Patrick I. Borgen, MD, discusses eliminating the use of opioids in patients with breast cancer.
What may have worked before to mitigate burnout may no longer work now because we change, and so do our work environments.
Genetic advances have helped elucidate the heterogenous nature of breast cancer, however optimal strategies for patients with early-stage disease still need to be ironed out.
The inclusion of patients from the time of diagnosis and encompassing family, friends, and caregivers is central to moving survivorship care forward, especially for breast cancer survivorship, which has high survival rates for early disease and the emergence of novel treatments for advanced cancers.
The paradigm for treating patients with HER2-positive breast cancer is changing throughout the spectrum of the disease as a result of recent clinical trial findings regarding novel and established treatment regimens, according to Sara A. Hurvitz, MD
Joyce A. O'Shaughnessy, MD, discusses the utility of targeting capivasertib in targeting Akt mutations in breast cancer.
Debu Tripathy, MD, discusses personalized therapy options in metastatic breast cancer.
The novel coronavirus spreading across the world represents a distinct challenge for all physicians, especially oncologists who commonly treat patients who have compromised immune systems.
Special attention to reducing the risk of cardiovascular disease should be a priority for long-term care of patients with breast cancer.
Patrick I. Borgen, MD, discusses the trend toward surgical de-escalation in patients with breast cancer.
Enrique Soto Pérez de Celis, MD, MSc, discusses nuances of treating older patients with breast cancer.
Novel antibody-drug conjugates have demonstrated high response rates in patients with heavily pretreated metastatic breast cancer, and ongoing studies targeting actionable cell-surface markers may further expand their clinical utility, according to Aditya Bardia, MD, MPH.
Hope S. Rugo, MD, discusses the pending approval of tucatinib in metastatic HER2-positive breast cancer and other potentially practice-changing agents in the pipeline.
Physicians should “get out there and test early and often,” to align with a potential new paradigm for genetic testing that allows anyone on the treatment team to identify and test individuals, with the specialist ultimately providing risk management, according to Kevin S. Hughes, MD, FACS.
